Thalys Medical Technology Group Inc
SSE:603716
Intrinsic Value
Thalys Medical Technology Group, Inc. engages in the research, development, production, and sale of in vitro diagnostic products. [ Read More ]
The intrinsic value of one
Thalys Medical Technology Group Inc
stock under the Base Case scenario is
14.86
CNY.
Compared to the current market price of 6.85 CNY,
Thalys Medical Technology Group Inc
is
Undervalued by 54%.
Thalys Medical Technology Group Inc's market capitalization is 1.4B CNY.
Thalys Medical Technology Group Inc stock price is 6.85 CNY.
Thalys Medical Technology Group Inc stock price (6.85 CNY) is 54% less than its Intrinsic Value (14.86 CNY).
Thalys Medical Technology Group Inc stock (5.13 CNY) is 25% less than its price (6.85 CNY). Open DCF Valuation
Thalys Medical Technology Group Inc stock price (6.85 CNY) is 72% less than its Relative Value (24.6 CNY). Open Relative Valuation
Thalys Medical Technology Group Inc.
Thalys Medical Technology Group Inc's Revenue has been growing by 3% per year for the last 3 years.
Thalys Medical Technology Group Inc has positive Gross Profit for the last twelve months.
Thalys Medical Technology Group Inc's ROIC (Return on Invested Capital) has decreased in the last 3 years from 6% to -3%.
Thalys Medical Technology Group Inc has negative Free Cash Flow for the last twelve months.
Thalys Medical Technology Group Inc has negative Operating Income for the last twelve months.
Thalys Medical Technology Group Inc's Revenue has dropped by 18% over the past 12 months.
Thalys Medical Technology Group Inc's D/E (Debt to Equity) is very low and is equal to 0.83.
Thalys Medical Technology Group Inc's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -3%.
Thalys Medical Technology Group Inc's long-term assets (4B CNY) exceed its long-term liabilties (2B CNY).
Thalys Medical Technology Group Inc's ROE (Return on Equity) has significantly decreased in the last 3 years from 6% to -10%.
Thalys Medical Technology Group Inc has a very low three-year average ROIC (Return on Invested Capital): 3%. The company is not efficient at using invested capital to generate operating income.
Thalys Medical Technology Group Inc's short-term assets (3B CNY) exceed its short-term liabilties (2B CNY).
Thalys Medical Technology Group Inc has negative Net Income for the last twelve months.
Thalys Medical Technology Group Inc's ROE (Return on Equity) for the past 12 months is negative and is equal to -10%.
Thalys Medical Technology Group Inc has negative three-year average ROE (Return on Equity): -3%. The company is not efficient at transforming stockholders' equity into net income.
Thalys Medical Technology Group Inc's Altman Z-Score is very low and is equal to 1.73.
Thalys Medical Technology Group Inc has positive Net Debt. This means that the company has more debt (1B CNY) than cash and short-term investments (255m CNY).
Valuation Backtest
Thalys Medical Technology Group Inc
Run backtest to discover the historical profit from buying and selling
Thalys Medical Technology Group Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Thalys Medical Technology Group Inc
Balance Sheet Decomposition
Thalys Medical Technology Group Inc
| Current Assets | 2.7B |
| Cash & Short-Term Investments | 254.7m |
| Receivables | 2B |
| Other Current Assets | 525.7m |
| Non-Current Assets | 977.3m |
| Long-Term Investments | 368.5m |
| PP&E | 224.7m |
| Intangibles | 177.2m |
| Other Non-Current Assets | 206.9m |
| Current Liabilities | 1.6B |
| Accounts Payable | 785.2m |
| Accrued Liabilities | 37.8m |
| Short-Term Debt | 572.2m |
| Other Current Liabilities | 196.8m |
| Non-Current Liabilities | 734m |
| Long-Term Debt | 582.8m |
| Other Non-Current Liabilities | 151.1m |
Earnings Waterfall
Thalys Medical Technology Group Inc
|
Revenue
|
2.1B
CNY
|
|
Cost of Revenue
|
-1.7B
CNY
|
|
Gross Profit
|
368.4m
CNY
|
|
Operating Expenses
|
-452.2m
CNY
|
|
Operating Income
|
-83.7m
CNY
|
|
Other Expenses
|
-69.5m
CNY
|
|
Net Income
|
-153.2m
CNY
|
Free Cash Flow Analysis
Thalys Medical Technology Group Inc
Profitability Score
Profitability Due Diligence
Thalys Medical Technology Group Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Thalys Medical Technology Group Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Thalys Medical Technology Group Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Thalys Medical Technology Group Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Thalys Medical Technology Group Inc
Shareholder Return
Price
Thalys Medical Technology Group Inc
| Average Annual Return | -13.6% |
| Standard Deviation of Annual Returns | 8.28% |
| Max Drawdown | -74% |
| Market Capitalization | 1.4B CNY |
| Shares Outstanding | 188 640 318 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Thalys Medical Technology Group Inc
Country
Industry
Market Cap
Dividend Yield
Description
Thalys Medical Technology Group, Inc. engages in the research, development, production, and sale of in vitro diagnostic products. The company is headquartered in Wuhan, Hubei and currently employs 1,637 full-time employees. The company went IPO on 2016-10-31. Its product type includes purchased reagents and consumables, self-produced reagents and consumables, as well as purchased equipment. The firm mainly operates its business in domestic markets, with Hubei, Hunan, Jiangsu, Henan and Shanghai province as its major markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Thalys Medical Technology Group Inc
stock under the Base Case scenario is
14.86
CNY.
Compared to the current market price of 6.85 CNY,
Thalys Medical Technology Group Inc
is
Undervalued by 54%.
You don't have any saved screeners yet
